Schinecker
Biotech

Roche CEO has ‘absolutely not’ changed view on Poseida buyout

CEO Thomas Schinecker, Ph.D., insisted to Fierce that his “opinion has not changed,” even as the pharma scrapped a CAR-T from the Poseida acquisition.
James Waldron Oct 22, 2026 4:16am
Saudi Arabia takes actionable steps to build its biotech sector after 46 agreements in Riyadh

Saudi Arabia takes actionable steps to build its biotech sector

baton handoff in track and field race

Menarini gets Georgiamune preclinical cancer drug in $1B deal

Oct 22, 2026 10:50am
From Scientific Hypothesis to Clinical Practice The Next Chapter for CLDN182

The next chapter of CLDN18.2-directed innovation

Brought to you by Astellas Pharma US
AbbVie

AbbVie posts phase 3 HS win but falls short of expectations

Oct 22, 2026 10:39am
Aligning drug discovery around patient benefit from the outset Connecting human insights to better decisions

Aligning drug discovery around patient benefit from the outset: Connecting human insights to better decisions

Brought to you by IQVIA Laboratories
More News

Celltrion picks up another Kaigene antibody for up to $580.5M

Oct 22, 2026 10:22am

Rebranded NodThera plans IPO to fund NLRP3 inhibitor program

Oct 22, 2026 5:27am

Using tumor ‘avatar’ to predict patients’ immunotherapy response

Oct 21, 2026 11:50am

Amid bepirovirsen triumph, GSK scraps trial of next-gen therapy

Oct 21, 2026 9:35am